Hand-foot syndrome and survival in patients with advanced non-small-cell lung cancer receiving anlotinib: a subgroup analysis of data from the ALTER 0303 study-Reference-Cited by-同舟云学术

Hand-foot syndrome and survival in patients with advanced non-small-cell lung cancer receiving anlotinib: a subgroup analysis of data from the ALTER 0303 study

Published:2020-05-24 Issue:8 Volume:25 Page:1492-1498
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Nan Xueli,Xie Chao,Zhu Qingqing,Zhang Jianjun,Fu Shuai,Han Xiao,Zhang Qiujing,Han Baohui,Liu Jie

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

https://link.springer.com/content/pdf/10.1007/s10147-020-01683-0.pdf

Reference29 articles.

1. Chen W, Zheng R, Baade PD et al (2015) (2016) Cancer statistics in China. CA Cancer J Clin 66(2):115–132. https://doi.org/10.3322/caac.21338

2. Miller KD, Nogueira L, Mariotto AB et al (2019) Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin 0:1–23. https://doi.org/10.3322/caac.2156

3. Maione P, Rossi A, Sacco PC et al. (2010) Advances in chemotherapy in advanced non-small-cell lung cancer. Expert Opin Pharmacother 11(18):2997–3007. https://doi.org/10.1517/14656566.2010.511615

4. Chan BA, Hughes BG (2015) Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res 4(1):36–54

5. Janne PA, van den Heuvel MM, Barlesi F et al (2017) Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS-mutant advanced non–small cell lung cancer: the SELECT-1 randomized clinical trial. JAMA 317(18):1844–1853. https://doi.org/10.1001/jama.2017.3438

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anlotinib as a third-line or further treatment for recurrent or metastatic nasopharyngeal carcinoma: a single-arm, phase 2 clinical trial;BMC Medicine;2023-11-07

2. Toripalimab combined with anlotinib for recurrent extensive‑stage small‑cell lung cancer: A case report;Experimental and Therapeutic Medicine;2023-05-12

3. Genomic profiling of non-small cell lung cancer with the rare pulmonary lymphangitic carcinomatosis and clinical outcome of the exploratory anlotinib treatment;Frontiers in Oncology;2022-10-17

4. Anlotinib plus platinum‐etoposide as a first‐line treatment for extensive‐stage small cell lung cancer: A single‐arm trial;Cancer Medicine;2022-05-08

5. Anlotinib plus nab-paclitaxel/gemcitabine as first-line treatment prolongs survival in patients with unresectable or metastatic pancreatic adenocarcinoma: a retrospective cohort;Annals of Translational Medicine;2022-03